Thiazolidinediones in dermatology.
Thiazolidinediones, also known as glitazones, represent a relatively new class of medication used for glycemic control in patients with type II diabetes mellitus. These drugs interact with the peroxisome proliferator-activated receptor gamma, a member of the nuclear receptor superfamily, which in turn heterodimerizes with retinoid X receptors to stimulate gene transcription. At a physiologic level, glitazones stimulate adipocyte differentiation, enhance insulin-sensitive glucose uptake by muscle and fat cells, suppress angiogenesis, inhibit tumor cell growth, and normalize keratinocyte differentiation. They have also demonstrated the capacity to diminish inflammatory cytokine production, most notably, that of tumor necrosis factor alpha. Patients with such disparate conditions as psoriasis, hirsutism, melanoma, angiosarcoma, lipodystrophy, and necrobiosis lipoidica have benefited from the administration of thiazolidinediones. Clinicians should become familiar with glitazones as they are experiencing a burgeoning use among patients with non-insulin-dependent diabetes mellitus and have demonstrated clinical efficacy in treating certain skin conditions.
Boyd
Alan S
AS
Department of Medicine (Dermatology), Vanderbilt University, Nashville, TN, USA. alan.boyd@vanderbilt.edu
D039682:HIV-Associated Lipodystrophy Syndrome / Q000188:drug therapy; D006628:Hirsutism / Q000188:drug therapy; D006801:Humans; D008545:Melanoma / Q000188:drug therapy; D047495:PPAR gamma / Q000819:agonists / Q000187:drug effects / Q000378:metabolism*; D011565:Psoriasis / Q000188:drug therapy; D047488:Retinoid X Receptors / Q000187:drug effects / Q000378:metabolism; D012871:Skin Diseases / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy; D045162:Thiazolidinediones / Q000494:pharmacology / Q000627:therapeutic use*; D014158:Transcription, Genetic / Q000187:drug effects; D019043:Vascular Neoplasms / Q000188:drug therapy
D047495:PPAR gamma; D047488:Retinoid X Receptors; D045162:Thiazolidinediones